ClinicalTrials.gg
CompletedNCT06912139Updated Apr 4, 2025

Topical Nitroglycerine for Prevention of Radial Artery Spasm

A Phase 3 interventional study of Nitroglycerin transdermal and Placebo in Radial Artery Spasm, sponsored by University of Medicine and Pharmacy "Victor Babes" Timisoara. Completed at 1 site in Romania. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by University of Medicine and Pharmacy "Victor Babes" Timisoara · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Apr 2023, registered Mar 2025).
Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In a randomized, double-blind trial, 100 patients undergoing angiography were pre-treated with either topical nitroglycerin (NTG) or placebo. Outcomes assessed included radial artery spam (RAS) incidence, radial artery puncture success, number of attempts, procedural duration, patient discomfort, and complications. RAS was evaluated angiographically and clinically, with additional subgroup analyses for diabetic and smoking patients

Read the detailed description

During the period of April 2023 - June 2023, 100 consecutive patients that un-derwent invasive angiography using radial artery approach (deemed suitable access site by operating physician) were enrolled and randomized to either pretreatment with a topical cream 0.2% NTG, or application of a gel that contained no active substances. Randomization was done using a computer program designed to randomly produce either the digit 1 or 0, with 1 meaning the patient was assigned to nitroglycerine cohort and 0 to placebo cohort. The assigned nurse that handled the randomization also ad-ministered the patient's treatment. The NTG or placebo cream was applied 20-40 minutes before radial artery puncture by the assigned nurse. The study was designed as a randomized, double-blinded trial, with neither the patient nor the operator aware of the treatment allocation. Patients had indication of either elective or emergency coronary artery or peripheral artery angiography, and had no contraindication to ra-dial artery approach. Both right and left radial arteries were used, depending on oper-ator judgement, while distal radial approach was not utilized in any case. The operator assessed the radial artery pulse quality by manual palpation before puncture. Standard local subcutaneous anesthesia with 5 ml of 2% lidocaine solution was performed. A visual analog scale was used to judge patient discomfort related to the puncture and puncture site at several times during the procedure, with the worst pain level being documented (scale of 0 to 10, where 0 is no pain, and 10 is worst possible pain). The key objective was assessing spasm of the radial artery, which was judged both subjectively by the operator by judging the grade of resistance felt during manipulation of the catheters, and objectively by injection of contrast dye into the radial artery through the introducer sheath immediately after it had been placed inside the radial artery. Spasm was defined as narrowing of the radial artery lumen by more than 50%. Diffuse spasm was defined as spasm of a segment of radial artery greater than 2 cm, or more than two different sites of spasm. The diameter of the radial artery was also measured on the radial angiograms, and was indexed to the patient's body surface area. After sheath insertion and radial artery measurement, the operator could administer intraarterial NTG at his discretion throughout the procedure.

Other data that was included was number of attempts that lead to successful puncture and sheath placement, procedure duration (including angioplasty if needed), contrast dye used and hospital stay duration. Patients were screened for cardiovascu-lar risk factors such as smoking, diabetes mellitus, dyslipidemia, hypertension and obesity. Procedural anticoagulation was performed using 5000 units of unfractioned heparin for diagnostic procedures and 70 units/kilogram for angioplasties. At the end of the procedure, after sheath extraction, hemostasis was achieved using a compres-sive dressing that was left in place for \~12 hours. Bleeding complications at the site of puncture were noted (presence of local hematoma), and ultrasound screening at dis-charge was used to check postprocedural radial artery patency.

Radial sheaths used were 6 French, and the operator had the freedom to use any size of catheters he considered, most often choosing 6 French for both diagnostic angi-ography and percutaneous intervention. No preprocedural patient sedation was used, and cath lab temperature was similar for all cases.

Statistical analysis was performed using IBM SPSS Statistics version 20.0 software for Windows with a significant p\<0.05. We used descriptive statistics, figures, and ta-bles to summarize our findings. Results for targeted variables were presented using descriptive statistics (mean, standard deviation, range, median, and associated inter-quartile range) for continuous data, and counts with associated percentages for cate-gorical data. Independent samples t-test was used to analyze differences in means for continuous variables, while differences between categorical variables were examined by Chi-squared test. Categorical data are presented as counts (percentages).

02

Conditions studied

  • Radial Artery Spasm

Browse trials for

Keywords

  • topical nitroglycerine
  • radial artery spasm
  • coronary angiography
  • radial puncture
03

In context

Spasm

123 studies on the registry are indexed under Spasm; 7 are open to participants now.

This study's enrollment of 100 is above the median of 80 across 104 interventional studies indexed under Spasm.

Browse Spasm studies →

Lead sponsor

University of Medicine and Pharmacy "Victor Babes" Timisoara is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • indication for invasive cardiology procedure (diagnostic or curative)
  • deemed suitable for radial access by operating physician

Exclusion criteria

Exclusion Criteria:

  • refuses or unable to give consent
  • demed unsuitable for radial artery access (no radial pulse, small patient size, anticipation of complex procedure that requires alternative access site)
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    nitroglycerin topic cream for radial artery spasm prevention, applied before radial artery puncture

    Drug: Nitroglycerin transdermal

  • Placebo comparator
    placebo cream administration

    Other: Placebo

Interventions

  • DrugNitroglycerin transdermal

    Nitroglycerin cream is applied \~ 15 minutes before radial artery puncture for emergency or planned invasive cardiology procedure (example: coronary angiography), and radial artery spasm and diameter are determined by angiography, injecting contrast into the radial artery through the placed radial sheath.

  • OtherPlacebo

    Placebo cream with no active compounds is applied by the designated nurse to the radial puncture site, similar to NTG cream, with both patient and invasive cardiologist blinded wo which arm the patient is included in.

06

What researchers measure

Primary outcomes

  1. Radial artery spasm as determined by angiography of radial artery; spasm being defined as >50% stenosis

    Time frame: Baseline

Secondary outcomes

  1. Number of radial artery puncture attempts

    Nitroglycerin cream is applied \~15 minutes before radial puncture is attempted, operator notes number of tries to successfully puncture it and place the sheath

    Time frame: Baseline

  2. Crossover to alternative puncture site

    If radial puncture is unsuccessful another puncture site is needed, this is noted by operator as need for cross-over

    Time frame: Baseline

  3. Radial artery diameter, absolute value

    Angiographical measurement of radial artery diameter in non-spastic area

    Time frame: Baseline

  4. Patient discomfort measured using a Visual Analog Scale

    The patient is asked throughout the procedure level of pain on a 0-10 scale, and maximum level is noted

    Time frame: Intraprocedural, every 15 minutes

  5. Radial artery spasm: diffuse or localized

    If radial spasm is present on a segment of radial artery longer than 20mm it is noted as diffuse, if shorter then it is noted as localized

    Time frame: Baseline

  6. Contrast medium used during procedure

    Total amount in milliliters l is noted

    Time frame: At the end of invasive procedure

  7. Invasive procedure duration

    Total duration of procedure is noted, from puncture of artery to catheter withdrawal (coronary angiography, angioplasty, other angiographic investigation)

    Time frame: at the end of invasive procedure

  8. Hospital stay duration

    Total length of hospitalization is noted (in days)

    Time frame: Up to 10 weeks

  9. Number of patients with radial artery patency at discharge

    Radial artery patency (of punctured artery) is determined by ultrasound analysis on the day of discharge

    Time frame: Up to 3 weeks

  10. Local complications at puncture site - hematoma

    During hospital stay, after procedure is completed, forearm is examined for local hematoma in relation to radial artery puncture site

    Time frame: Up to 3 weeks

  11. Radial artery diameter indexed to body surface area

    Angiographical measurement of radial artery diameter in non-spastic area indexed to patient body surface area

    Time frame: Baseline

07

Study locations

1 site
  • Timisoara Institute for Cardiovascular Diseases
    Timisoara, Timis 300134, Romania
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06912139
Lead sponsor
University of Medicine and Pharmacy "Victor Babes" Timisoara
Responsible party
Basaraba Gabriela Lavinia (Legal entity appointed representative, University of Medicine and Pharmacy "Victor Babes" Timisoara) — Principal investigator
First posted
Apr 4, 2025
Start date
Apr 1, 2023
Primary completion
Jun 30, 2023
Completion
Jun 30, 2023
Last update
Apr 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion